Edition:
India

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

1.27USD
22 Nov 2017
Change (% chg)

$-0.03 (-1.92%)
Prev Close
$1.30
Open
$1.30
Day's High
$1.30
Day's Low
$1.27
Volume
4,613
Avg. Vol
30,439
52-wk High
$5.20
52-wk Low
$1.10

Summary

Name Age Since Current Position

Mark Perrin

58 2015 Chairman of the Board, Chief Executive Officer

Christopher McNulty

40 2017 Principal Financial Officer and Principal Accounting Officer

Melanie Morel-Ferris

36 2017 Senior Director, Finance and Controller

Tamara Joseph

52 2014 Senior Vice President, Chief Compliance Officer, General Counsel

Pamela Stahl

48 2016 Chief Commercial Officer

Richard Toselli

2017 Chief Medical Officer

Ann Merrifield

66 2015 Lead Independent Director

Jeffrey Hatfield

2016 Director

Christina Morrison

48 2016 Director

Kenneth Di Pietro

58 2012 Independent Director

Daniel Marshak

58 2014 Independent Director

Richard Roberts

71 2010 Independent Director

Biographies

Name Description

Mark Perrin

Mr. Mark D. Perrin is Chairman of the Board, Chief Executive Officer of Invivo Therapeutics Holdings corp. Prior to joining the company, Mr. Perrin served as President of Dennan Consulting, a biotech consulting firm, from June 2012 to December 2013. From November 2005 to October 2010, Mr. Perrin was President and Chief Executive Officer of ConjuChem Biotechnologies, Inc., a company developing long-acting conjugated peptide therapeutics. In 2010, ConjuChem filed a voluntary assignment in bankruptcy under the Canadian Bankruptcy and Insolvency Act in order to effect an orderly liquidation of its assets, property and operations. Prior to joining ConjuChem, Mr. Perrin was Executive Vice President and Chief Commercial Officer of Orphan Medical, Inc. from 2002 to 2005, when it was acquired by Jazz Pharmaceuticals. From 1995 to 2001, he was Executive Vice President, Commercial Operations of COR Therapeutics, Inc., where he created and developed sales, marketing, and manufacturing functions for the emerging company. Before that, he served as Vice President of Marketing and Sales for Burroughs Wellcome Company where he headed all commercial operations in the United States from 1992 to 1995.

Christopher McNulty

Mr. Christopher McNulty is Principal Financial Officer and Principal Accounting Officer of the company. He has served as the Company’s Senior Vice President, Business Development & Investor Relations, since August 2015. In that role, he has led the Company’s business development and partnering activities as well as corporate communications, including investor relations and public relations. From June 2014 to August 2015, he served as the Company’s Vice President, Business Development and Investor Relations, and from November 2013 to July 2014, he served as the Company’s Vice President, Business Development. Prior to joining the Company, Mr. McNulty served at Repligen Corporation, a pharmaceutical and bioprocessing company, from 2010 to 2013, most recently as Senior Director of Business Development. From 2009 to 2010, he was Director of Corporate Development at Seventh Sense Biosystems, Inc., a medical device company. From 2006 to 2009, Mr. McNulty served at Genzyme Corporation, a biotechnology company, most recently as Associate Director of Alliance Management and Business Development. Before joining Genzyme, Mr. McNulty held technical roles at Transform Pharmaceuticals, Inc. from 2000 to 2004 and at Cereon Genomics, LLC from 1998 to 2000. Mr. McNulty received his B.S. and M.Eng. degrees in electrical engineering and computer science from the Massachusetts Institute of Technology. He also holds an M.B.A. from Harvard Business School.

Melanie Morel-Ferris

Ms. Melanie Morel-Ferris is Senior Director, Finance and Controller of the Company. Ms. Morel-Ferris has served as the Company’s Controller since May 2016. Prior to joining the Company, Ms. Morel-Ferris served as the Corporate Controller of Astrodyne TDI, an electrical manufacturing company from July 2014 to May 2016. Prior to that, Ms. Morel-Ferris served as the Associate Director of Corporate Accounting of ARIAD Pharmaceuticals, Inc., a drug development company, from January 2014 to July 2014 and as a Senior Accounting Manager at ARIAD from January 2011 to December 2013. Ms. Morel-Ferris began her career at Deloitte. Ms. Morel-Ferris received a B.A. from Assumption College and is a Certified Public Accountant.

Tamara Joseph

Ms. Tamara L. Joseph has been appointed as Senior Vice President, Chief Compliance Officer, General Counsel of the Invivo Therapeutics Holdings Corp., effective March 24, 2014. Ms. Joseph was appointed as an independent director of the public health non-profit PHFE in February 2013. She is the Vice Chair of PHFE's Board of Directors and is a member of its Audit Committee and its Governance and Nominating Committee. She previously served as Senior Vice President, General Counsel of Cubist Pharmaceuticals, Inc. from April 2008 to October 2012, where she was responsible for the law, compliance, risk management and government affairs departments. Prior to that, she served as Executive Vice President, General Counsel of Mayne Pharma Ltd., from 2006 to 2008. Before that, Ms. Joseph served as Vice President, General Counsel of Transkaryotic Therapies, Inc., and from 1998 to 2005, Ms. Joseph led the Biogen Idec legal department's operations outside the United States as Vice President, International Legal. Ms. Joseph began her legal career as a litigator with Fried, Frank, Harris, Shriver & Jacobson and later with Morrison & Foerster.

Pamela Stahl

Ms. Pamela J. Stahl is Chief Commercial Officer of the Company., effective September 14, 2016. Prior to joining InVivo, Ms. Stahl served for 10 years in various roles of increasing responsibility at UnitedHealthcare, most recently as Chief Executive Officer, Community Health Plan of Wisconsin. In that role, she was responsible for the largest Medicaid business in the state, providing healthcare benefits and services for over 160,000 Wisconsin residents. Ms. Stahl also held other Senior Vice President roles at UnitedHealthcare with responsibilities for the Office of the Consumer; Sales Operations and Organizational Effectiveness; the Women's Health Line of Service; and Consumer Marketing. Prior to UnitedHealthcare, Ms. Stahl was Vice President, Sales and Commercial Operations for Orphan Medical, Inc. from 2001 to 2006. She built and supervised a specialty sales force and established the sales operation function, implemented a risk management program, and created the patient affairs department. Before that, she served as Vice President, Sales and Marketing for American TeleCare, Inc. From 1992 until 2000 she held various sales and marketing roles of increasing responsibility at AstraZeneca, including Regional Marketing Manager, Account Team Leader, Customer Unit Director, Product Optimization Leader, and Regional Sales Director. Ms. Stahl began her sales career at Merck & Co. Inc.

Richard Toselli

Dr. Richard Toselli, M.D., has been appointed as Chief Medical Officer of the Company, with effective from July 5, 2017. Prior to joining InVivo, Dr. Toselli served as Chief Medical Officer for Cochlear Limited. In that role, he was responsible for global clinical, regulatory, and medical affairs teams reporting to the CEO. Prior to that, Dr. Toselli served five years at Sanofi in various levels of increasing responsibility, including Vice President of Global Medical Affairs – Immunology and Inflammation, Biologics Division; Vice President of Global Medical Affairs and Head of the Biosurgery Discovery Performance Unit; and Vice President of Global Medical Affairs, Biosurgery. Before his time at Sanofi, he served as Chief Medical/Technology Officer for Covidien Surgical, and earlier held various roles at DePuy Spine including Director of Medical Affairs, Worldwide Vice President of Research and Development, and Worldwide Vice President of Clinical Evidence and External Relations. He subsequently held the position of Vice President of Evidence-Based Medicine at Johnson & Johnson for the device sector. Dr. Toselli's previous academic positions include Assistant Professor at Brown University, Associate Professor, Director of Spine Center, and Associate Chief of Staff at the University of North Carolina (UNC), and Associate Professor at the University of Vermont. He holds a bachelor of arts from Providence College, his medical degree from Brown University, and a masters of business administration from the UNC's Kenan-Flagler Business School. Dr. Toselli is a board-certified neurological surgeon.

Ann Merrifield

Ms. Ann Merrifield is Lead Independent Director of the Company. She was Independent Director of Invivo Therapeutics Holdings Corp. Before joining PathoGenetix in 2012, She also serves as a director of Flexion Therapeutics, a public biotechnology company. Ms. Merrifield most recently served as President, Chief Executive Officer, and a director of PathoGenetix, Inc., a genomics company focused on developing an automated system for rapid bacterial identification, from 2012 until July 2014 when the company filed for Chapter 7 bankruptcy. Prior to then, she spent 18 years at Genzyme Corporation, serving in a number of leadership roles including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President, Business Excellence. Ms. Merrifield also serves as trustee and director on several boards including Partners Continuing Care, the non-acute care services division of Partners HealthCare; the YMCA of Greater Boston; and MassMutual Premier, MML, and Select/MML II Funds.

Jeffrey Hatfield

Mr. Jeffrey S. Hatfield serves as Director of the Company. Prior to joining Vitae Pharmaceuticals, Mr. Hatfield worked at Bristol-Myers Squibb (BMS) in a variety of executive positions, including: Senior Vice President of BMS' Immunology and Virology Divisions, where he was responsible for all aspects of the $1B annual revenue division; President and General Manager, BMS-Canada; and Vice President, U.S. Managed Health Care. Mr. Hatfield holds an M.B.A. from The Wharton School of the University of Pennsylvania and a bachelor's degree in pharmacy from Purdue University, where he is a Distinguished Alumnus and adjunct professor. He has served on the Board of Ambit Biosciences (AMBI) before its acquisition by Daiichi-Sankyo, and is currently a member of the Board of Directors of the Biotechnology Industry Organization (BIO), serving on the Executive Committee of the Emerging Company Section. He is also a member of the advisory committees for Purdue University's College of Pharmacy, Drexel University's LeBow College of Business, and the Chapman-KGI School of BioPharmacy.

Christina Morrison

Ms. Christina T. Morrison is Director of the Company. Prior to joining Aramark, Ms. Morrison was Senior Vice President of Business and Financial Planning at Merck & Co., Inc. from November 2009 to June 2013. She was responsible for the company-wide planning, forecasting and budgeting processes, data and process standardization, and developing more automated reporting capabilities. Ms. Morrison's previous experience includes five years at Wyeth, beginning in April 2004, as the Vice President of New Business in the Women's Health Care division. In November 2005, she was appointed Vice President and Chief Financial Officer for Wyeth U.S. Pharmaceuticals, and in July 2007, she was promoted to Senior Vice President and Chief Financial Officer for Wyeth Pharmaceuticals. In that role, she was responsible for the global planning and reporting of the $20 billion pharmaceutical division. Ms. Morrison started her career as an analyst in the Mergers and Acquisitions Department at Alex. Brown & Sons, an investment bank (now Deutsche Bank). During her 12 years at Deutsche Bank, she held increasingly responsible positions, her last being Managing Director, Health Care Group. Ms. Morrison has been a member of the Board of Overseers of the Tuck School of Business at Dartmouth College since May 2011. She has also been a Member of the Board of Angel Flight East, a non-profit organization, since May 2014. Ms. Morrison graduated cum laude from the Wharton School at the University of Pennsylvania with a Bachelor of Science degree in Economics in 1989 and the Tuck School of Business at Dartmouth College in 1993 with an MBA.

Kenneth Di Pietro

Mr. Kenneth A. Di Pietro is Independent Director of InVivo Therapeutics Holdings Corp. Since February 2012, Mr. DiPietro has served as Executive Vice President, Human Resources of Biogen, Inc., a publicly-traded biotechnology company, since January 2012. Mr. DiPietro joined Biogen from Lenovo Group, where he served as Senior Vice President, Human Resources from May 2005 until June 2011. From 2003 to 2005, he served as Corporate Vice President, Human Resources at Microsoft Corporation, and as Vice President, Human Resources at Dell Inc. from 1999 to 2002. Prior to that, he spent 17 years at PepsiCo, serving in a range of human resource and general management positions.

Daniel Marshak

Mr. Daniel R. Marshak, Ph.D is Independent Director of Invivo Therapeutics Holdings Corp., effective September 29, 2014. He most recently served as Senior Vice President and Chief Scientific Officer for PerkinElmer, Inc. until September 2014. Prior to joining PerkinElmer in 2006, Dr. Marshak was Vice President and Chief Technology Officer, Biotechnology, for Cambrex Corporation. Dr. Marshak has received numerous awards for scientific and academic achievements and is named as inventor on six issued U.S. patents. He currently serves on the International Society for Stem Cell Research Global Advisory Council and served on their board of directors from July 2008 to June 2014. Dr. Marshak is the author of more than 100 scientific publications, including one textbook, and has been the editor of five monographs. He recently held an appointment as Adjunct Associate Professor at the Johns Hopkins University School of Medicine and previously taught graduate biochemistry as an Assistant Professor at the State University of New York.

Richard Roberts

Dr. Richard J. Roberts, Ph.D., is an Independent Director of Invivo Therapeutics Holdings Corp., since October 26, 2010. Dr. Roberts initially joined InVivo Therapeutics Corporation's Scientific Advisory Board in June 2007 and continues as a member of our Scientific Advisory Board. He has served as Chief Scientific Officer at New England Biolabs since February 2007. Dr. Roberts was awarded the 1993 Nobel Prize in Physiology of Medicine along with Phillip Allen Sharp for the discovery of introns in eukaryotic DNA and the mechanism of gene-splicing.